Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma

Expert Opin Ther Targets. 2019 Feb;23(2):83-86. doi: 10.1080/14728222.2019.1559828. Epub 2018 Dec 17.

Authors

Kyrillus S Shohdy¹, Panagiotis J Vlachostergios², Raafat R Abdel-Malek¹, Bishoy M Faltas²

Affiliations

¹ a Clinical Oncology Department , Kasr Alainy School of Medicine, Cairo University , Cairo , Egypt.
² b Division of Hematology and Medical Oncology, Department of Medicine , Weill Cornell Medical College , New York , NY , USA.

PMID: 30558440
DOI: 10.1080/14728222.2019.1559828

No abstract available

Keywords: Urothelial carcinoma; cyclin-dependent kinase 4/6 inhibitors; fibroblast growth factor receptor.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / pharmacology*
Cyclin-Dependent Kinase 4 / antagonists & inhibitors
Cyclin-Dependent Kinase 6 / antagonists & inhibitors
Humans
Molecular Targeted Therapy*
Receptors, Fibroblast Growth Factor / antagonists & inhibitors
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / pathology

Substances

Antineoplastic Agents
Receptors, Fibroblast Growth Factor
CDK4 protein, human
CDK6 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6